Ezetimibe Dides fluoro impurity

Ezetimibe Dides fluoro impurity is a structurally related degradation byproduct of the parent drug, arising from the removal of two fluorine atoms from the 4-(4,5-dihydro-1,2,4-triazol-3-yl)-6-phenyldioxan-2-one core. This impurity retains the tetrahydrofuran ring and triazole moiety but features a defluorinated phenyl substituent, altering electronic and steric properties. Its precise application lies in HPLC-based quantification of process-related impurities in ezetimibe active pharmaceutical ingredient batches.